Fig. 2From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization studyMedian and 25th and 75th percentile LDLC (mg/dl) at study entry and 4, 12, and 24Â weeks follow-up on Alirocumab 150Â mg every two weeksBack to article page